Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The goal of this study is to determine the safety of pharmacogenetic guided dosing of epirubicin for each UGT2B7 genotype.
Primary Objectives To describe the side effects of pharmacogenetically individualized FEC chemotherapy in the adjuvant and neoadjuvant treatment of breast cancer.
Michael B Sawyer, MD FRCPC BScPharm
Alberta Health Services
Canada: Health Canada